Author response for "Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2" | NobleID
v1
Author response for "Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2"
Simone Bastrup Israelsen, Anton Pottegård, Håkon Sandholdt, Sten Madsbadand 2 more